PD-L1 as a Biomarker Predictive of Response to Checkpoint Inhibition in Lung Cancer
A review of data regarding PD-L1 expression as a predictive biomarker of response to checkpoint inhibition in lung cancer.
Immune Checkpoint Inhibitors for Renal Cell Carcinoma
It is estimated that 1 in 63 individuals in the United States will develop renal cell carcinoma (RCC), making it among the most common cancers in the country.
2 Clarke Drive Cranbury, NJ 08512